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Clinics 
Age and sex: 75 years old female patient. 
Organomegaly:  
- hepatomegaly;  
- splenomegaly;  
- enlarged lymph nodes;  
- no central nervous system involvement. 
Previous history:  
- B-cell Lymphoproliferative disorder for 8 years; 
- A 75-years-old female with an 8 years diagnosis of 
mature B-cell proliferation disorder. At August, 1999 a 
CBC showed high WBC, and physical examination 
showed enlarged lymph nodes (cervical and axillaries). 
Peripheral blood revealed Hb: 14,8g/dl, WBC: 21,8 x 
109/l, lymphocytes 16 x 109/l, platelets 241 x 109/l and 
bone marrow trephine showed interstitial infiltration 
with small lymphocytes consistent with CLL stage A 
(Binet). In April, 2000 there was a significant increase 
in the lymph nodes and night sweats. PB 
immunophenotyping study showed a CD19/CD5 
positive population consisted with B-CLL (Matutes' 
score 4). The patient was treated with 6 cycles of COP, 
with evolution to pulmonary nodules and axillae bulky 
in 2001. From 2001 to 2004, a few cycles of 
Chlorambucil and 7 cycles of R-COP produced a good 
response. In April, 2005, the PB morphology and 
immunophenotype were consistent to atypical B-CLL 
(CD19, CD20, CD23, CD25, HLA-DR, IgM, IgD, 
CD79b, CD38, and sKappa,positive and CD5 
negative), and PB karyotype showed no clonal 
abnormalities in 20 metaphases. In August, 2005, there 
was an increased in the number of lymph nodes and 
Rituximab and Fludarabine was started. The PB counts 
showed: Hb: 13g/dl, WBC: 69,6 x 109/l, lymphocytes: 
62 x 109/l, platelets: 145 x 109/l. Inguinal lymph node 
biopsy showed diffuse large B-cell Lymphoma, Ki-67: 
70%, cyclin D1 -, CD20 +, BCL2 +. From December, 
2005 to April, 2006, 6 cycles of R-CHOP showed no 
response. From October, 2006 to May, 2007, regression 
of lymph nodes and clinical improvement was done 
with 6 cycles of MiCEP. At this time, cytogenetics and 
immunophenotyping studies of bone marrow were 
performed. 
Blood 
WBC: 5,4 x 109/l; Hb: 13,6 g/dl; platelets: 169 x 109/l; 
blasts: 3,35 x 109/l (lymphoid cells)%. 
Bone marrow: 28% of lymphoid mature cells. 
Cytopathology classification 
Cytology: B-cell Lymphoproliferative disorder 
(Atypical CLL) with evolution to diffuse large B-cell 
Lymphoma. Atypical CLL. 
Immunophenotype: 25% of total bone marrow cells are 
positive : CD20++, CD22+, CD25+, CD38, CD79b++, 
HLA-DR, sIgM, sIgD e sKappa ++. 
Rearranged Ig or Tcr: not done. 
Pathology: Inguinal Lymph node biopsy (August, 
2005): Diffuse large B-cell Lymphoma, Ki-67: 70%, 
ciclina D1 -, CD20 +, BCL2 +. 
Electron microscopy: not done. 
Precise diagnosis: B-cell Lymphoproliferative disorder 
(Atypical CLL) with evolution to diffuse large B-cell 
Lymphoma. 
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Survival 
Date of diagnosis: 07-2007. 
Treatment: wide previous history (long previous history 
of chemotherapy), no chemotherapy after July, 2007. 
Complete remission: not applied. 
Treatment related death: - 
Relapse: - 
Status: Alive 09-2007. 
Survival: 2 months. 
Karyotype 
Sample: bone marrow cells; culture time: 72 hours with
and without TPA (o-tetradecanoyl phorbol-13-acetate); 
banding: G; results: 47, XX, t(1;6)(p35;p25), 
+12[13]/46,XX[7]. 
Karyotype at relapse: not done. 
Other molecular cytogenetic techniques: not done. 
Other molecular studies 
Technics: not done 
 
Partial karyotype, G-band. 
Comments 
In 2005, the Belgian group described the 
t(1;6)(p35.3;p25.2) in 8 patients with unmutated B-
CLL. As in this case, this rare cytogenetic entity has 
been described in typical or atypical CLL (8/8 cases), 
with evolution to diffuse large B-cell Lymphoma (3/8 
cases); trisomy 12 been a common additional 
abnormality (3/8 cases). 
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